Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CureVac (CVAC) EPS (Weighted Average and Diluted) (2021 - 2025)

Historic EPS (Weighted Average and Diluted) for CureVac (CVAC) over the last 5 years, with Q3 2025 value amounting to $282587.6.

  • CureVac's EPS (Weighted Average and Diluted) rose 515.51% to $282587.6 in Q3 2025 from the same period last year, while for Sep 2025 it was $282587.6, marking a year-over-year increase of 515.51%. This contributed to the annual value of $0.77 for FY2024, which is 16060.04% up from last year.
  • Per CureVac's latest filing, its EPS (Weighted Average and Diluted) stood at $282587.6 for Q3 2025, which was up 515.51% from -$120744.0 recorded in Q2 2025.
  • In the past 5 years, CureVac's EPS (Weighted Average and Diluted) ranged from a high of $282587.6 in Q3 2025 and a low of -$223293.5 during Q1 2024
  • Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$109284.4 (2024), whereas its average is -$55356.3.
  • Per our database at Business Quant, CureVac's EPS (Weighted Average and Diluted) crashed by 3950.29% in 2022 and then skyrocketed by 53621.17% in 2024.
  • Quarter analysis of 5 years shows CureVac's EPS (Weighted Average and Diluted) stood at -$64700.5 in 2021, then decreased by 15.25% to -$74567.2 in 2022, then grew by 17.38% to -$61606.3 in 2023, then skyrocketed by 536.21% to $268734.0 in 2024, then increased by 5.16% to $282587.6 in 2025.
  • Its EPS (Weighted Average and Diluted) was $282587.6 in Q3 2025, compared to -$120744.0 in Q2 2025 and $226452.2 in Q1 2025.